Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m⁶A/p21 pathway.

ABSTRACT: Evidence suggests that metformin might be a potential candidate for breast cancer treatment. Yet, its relevant molecular mechanisms remain to be fully investigated. We found that metformin could suppress the N6-methyladenosine (m⁶A) level in breast cancer cells significantly. The latter has an essential role in breast cancer progression and is newly considered as a therapeutic target. In this study, we measured the m⁶A level by m⁶A colorimetric analysis and dot blot assay. We then performed qRT-PCR, western blot, MeRIP, dual-luciferase reporter assay, and others to explore the m⁶A-dependent pathway associated with metformin. In vivo effect of metformin was investigated using a mouse tumorigenicity model. In addition, breast cancer and normal tiss

SUBMITTER: Cheng L 

PROVIDER: S-EPMC7801402 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature